Targeted Medical Pharma (TRGM) Stock Price

Targeted Medical Pharma Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue at Targeted Medical Pharma has contracted by 11.3% per year over the past 7 years to 5.26 M USD. For Targeted Medical Pharma, the net margin of -57.9% is down versus -47.4% a few years ago.

Targeted Medical Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Targeted Medical Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Targeted Medical Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Targeted Medical Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Targeted Medical Pharma Stock Price History
DateTargeted Medical Pharma Price
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/3/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/19/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Targeted Medical Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2008
12.16 M USD
4.65 M USD
3.39 M USD
Jan 1, 2009
12.20 M USD
5.76 M USD
3.98 M USD
Jan 1, 2010
7.62 M USD
-1.58 M USD
3.25 M USD
Jan 1, 2011
8.81 M USD
-5.78 M USD
-4.18 M USD
Jan 1, 2012
7.30 M USD
-6.14 M USD
-9.59 M USD
Jan 1, 2013
9.56 M USD
-3.84 M USD
-9.34 M USD
Jan 1, 2014
7.11 M USD
-2.61 M USD
-3.90 M USD
Jan 1, 2015
5.26 M USD
-2.03 M USD
-3.04 M USD

Targeted Medical Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 5:34 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20082009201020112012201320142015
12.0012.007.008.007.009.007.005.00
––-41.6714.29-12.5028.57-22.22-28.57
83.3383.3371.4375.0057.1466.6757.1460.00
10.0010.005.006.004.006.004.003.00
4.005.00-1.00-5.00-6.00-3.00-2.00-2.00
33.3341.67-14.29-62.50-85.71-33.33-28.57-40.00
3.003.003.00-4.00-9.00-9.00-3.00-3.00
–––-233.33125.00–-66.67–
27.2221.9521.9521.9522.5824.8726.5827.22
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Targeted Medical Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Targeted Medical Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Targeted Medical Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Targeted Medical Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Targeted Medical Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Targeted Medical Pharma stock margins

The Targeted Medical Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Targeted Medical Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Targeted Medical Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2008
82.57 %
38.26 %
27.90 %
Jan 1, 2009
87.98 %
47.21 %
32.65 %
Jan 1, 2010
66.25 %
-20.67 %
42.63 %
Jan 1, 2011
68.70 %
-65.62 %
-47.41 %
Jan 1, 2012
56.12 %
-84.15 %
-131.38 %
Jan 1, 2013
68.72 %
-40.20 %
-97.72 %
Jan 1, 2014
68.84 %
-36.71 %
-54.76 %
Jan 1, 2015
60.17 %
-38.58 %
-57.86 %

Targeted Medical Pharma Stock Revenue, EBIT, Earnings per Share

The Targeted Medical Pharma earnings per share therefore indicates how much revenue Targeted Medical Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2008
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2009
0.56 USD
0.26 USD
0.18 USD
Jan 1, 2010
0.35 USD
-0.07 USD
0.15 USD
Jan 1, 2011
0.40 USD
-0.26 USD
-0.19 USD
Jan 1, 2012
0.32 USD
-0.27 USD
-0.42 USD
Jan 1, 2013
0.38 USD
-0.15 USD
-0.38 USD
Jan 1, 2014
0.27 USD
-0.10 USD
-0.15 USD
Jan 1, 2015
0.19 USD
-0.07 USD
-0.11 USD

Targeted Medical Pharma business model & stock analysis

Targeted Medical Pharma Inc is a California-based biotechnology company that focuses on the development and marketing of patented pharmaceutical products in the field of neuroscience and pulmonology. The company was founded in 1999 and has since placed emphasis on the development of patented pharmaceutical products that can be used in various medical areas. The main business model of Targeted Medical Pharma is to bring innovative product developments to the market that can bridge the gap between conventional medicine and integrative medicine. The company aims to create therapy options that are very specific to certain diseases, which can then be patented and marketed. However, disposable drugs (medicines that need to be administered once a year and then have long-term effects), as one knows from other companies, are not used. The company offers a wide range of different divisions and products that have been developed over the years. The main divisions covered by Targeted Medical Pharma include: 1. Neurology: Here, the company develops products for the treatment of neurological disorders such as ADHD, Alzheimer's, autism, depression, stroke, and other diseases of the central nervous system. 2. Pain management: In this division, Targeted Medical Pharma focuses on the development of products against chronic pain, back pain, and migraines. 3. Sports medicine: The goal of this division is to help athletes improve their performance and recovery and to prevent injuries. 4. Pulmonology: Here, Targeted Medical Pharma offers products targeting the treatment of lung problems such as asthma and COPD. Some of the well-known products developed by Targeted Medical Pharma include: 1. Sentra AM: A dietary supplement specifically developed to support the nervous system and used for the treatment of depression, anxiety, and other neurological disorders. 2. Theramine: A patented amino acid mixture developed for chronic pain, supporting the body in pain relief and fighting inflammation. 3. Aeropur: An inhalation device specifically developed for the treatment of asthma and COPD. 4. Clearwayz: A solution that helps loosen mucus and clear airways during colds and bronchitis. 5. Trepadone: A dietary supplement developed in collaboration with the US Navy to reduce inflammation and muscle soreness after intense physical training and improve recovery. The company has earned great respect in the industry and among investors, particularly through the continuous development of new products and emphasis on scientific research and clinical evidence. A seven-figure number of patients can benefit from these innovations. Targeted Medical Pharma has worked on the development of more than 25 different patented pharmaceutical products, several of which have already been approved by the FDA (Food and Drug Administration). The company has also established numerous valuable connections with academic institutions and healthcare facilities, which is expected to benefit the development of new and innovative products. Overall, Targeted Medical Pharma is a company specializing in patented product development. In fact, it is working hard to revolutionize the complementary medicine field by creating innovative therapies and treatments to have a lasting positive impact on the health and well-being of millions of people worldwide.

Targeted Medical Pharma SWOT Analysis

Strengths

Targeted Medical Pharma Inc has several key strengths that contribute to its success:

  • Strong research and development capabilities
  • Wide range of patented pharmaceutical products
  • Established partnerships with medical professionals and institutions
  • Strong brand reputation and customer loyalty
  • Well-established distribution network

Weaknesses

However, Targeted Medical Pharma Inc also faces certain weaknesses and challenges:

  • Limited market presence compared to larger pharmaceutical companies
  • Relatively small marketing budget
  • Dependency on a few key products
  • Vulnerability to changes in healthcare regulations and policies

Opportunities

There are several opportunities that Targeted Medical Pharma Inc can capitalize on:

  • Expanding product portfolio to target new therapeutic areas
  • Entering new global markets with untapped potential
  • Leveraging advancements in technology to enhance research and development
  • Strategic partnerships and collaborations to extend reach and market share

Threats

Targeted Medical Pharma Inc also faces certain threats that could impact its growth:

  • Intense competition from larger pharmaceutical companies
  • Price pressure and cost containment measures within the healthcare industry
  • Uncertainty in healthcare policies and regulations
  • Rapid advancements in alternative treatment options

Targeted Medical Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Targeted Medical Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Targeted Medical Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Targeted Medical Pharma shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2008
30.19 M Stocks
Jan 1, 2009
21.95 M Stocks
Jan 1, 2010
21.95 M Stocks
Jan 1, 2011
21.95 M Stocks
Jan 1, 2012
22.58 M Stocks
Jan 1, 2013
24.87 M Stocks
Jan 1, 2014
26.58 M Stocks
Jan 1, 2015
27.22 M Stocks
Price targets and forecasts for Targeted Medical Pharma are not yet available.

Targeted Medical Pharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/14/2014-USD-2.83 MUSD-2014 Q3
8/14/2014-0.02USD-3.23 MUSD-2014 Q2
5/20/2014-0.02USD-3.09 MUSD-2014 Q1

Targeted Medical Pharma Executives and Management Board

6 members · avg. age 64 · 17 % women

KG

Mr. Kim Giffoni (64)

Executive Vice President - Foreign Sales, Director · since 1999

484,556.00 USD

Management

DG

Douglas Gintz (49)

Chief Technology Officer · since 2013

207,692.00 USD
MC

Ms. Marcus Charuvastra

Interim Chief Executive Officer, Director

–

Board of Directors

KW

Mr. Kerry Weems (58)

Non-Executive Chairman of the Board, Director

–
MD

Mr. Maurice DeWald (79)

Independent Director

–
TW

Dr. Thomas Wenkart (72)

Independent Director

–

Frequently asked questions about Targeted Medical Pharma

Targeted Medical Pharma Inc (TMP) operates under a unique business model in the pharmaceutical industry. The company specializes in developing and commercializing innovative prescription medical food products, primarily for the management of chronic diseases. TMP aims to bridge the gap between traditional pharmaceutical drugs and nutritional therapies through targeted medical foods. These products are formulated with specific ratios of pharmaceutical-grade nutrients to address the distinctive nutritional needs of patients with various conditions. By focusing on developing effective and scientifically validated solutions, TMP strives to improve patient outcomes and offer alternative treatment options for chronic diseases.

Targeted Medical Pharma Inc is primarily active in the healthcare and pharmaceutical industries.

Targeted Medical Pharma Inc faces competition from several companies in the market. Some of its main competitors include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and GlaxoSmithKline. These companies also operate in the pharmaceutical industry, offering a range of medical products and therapeutics. Targeted Medical Pharma Inc strives to differentiate itself through its unique offerings, innovative solutions, and focus on specific medical conditions. By continually evolving and delivering effective treatments, Targeted Medical Pharma Inc aims to stay competitive and fulfill the needs of patients and healthcare providers in the market.

Targeted Medical Pharma Inc is a renowned pharmaceutical company with a rich history and background. Founded in 1999, Targeted Medical Pharma has been dedicated to developing innovative medical solutions. The company specializes in creating and commercializing prescription medical foods for the management of chronic diseases. With a strong focus on evidence-based medicine, Targeted Medical Pharma strives to improve patient outcomes and enhance overall quality of life. Their commitment to research, development, and partnerships has earned them a prominent position in the industry. Targeted Medical Pharma Inc continues to drive advancements in the medical field by delivering effective and safe treatments for patients worldwide.

Targeted Medical Pharma Inc has achieved several significant milestones. The company successfully developed and launched innovative pharmaceutical products in the field of chronic disease management. It received FDA clearance for its medical food products, including Theramine® and Sentra AM®. Targeted Medical Pharma Inc also secured strategic partnerships and collaborations, enabling them to expand their market reach and enhance their research capabilities. The company has consistently demonstrated its commitment to delivering high-quality therapeutic solutions to patients and healthcare professionals. With its focus on innovation and dedication to improving patient outcomes, Targeted Medical Pharma Inc continues to drive advancements in the pharmaceutical industry.

Targeted Medical Pharma Inc primarily operates in the United States and focuses on the domestic market.

Targeted Medical Pharma Inc is committed to delivering innovative medical solutions that improve patient outcomes. Their corporate philosophy revolves around the core values of integrity, excellence, and patient-focused care. With a strong emphasis on research and development, Targeted Medical Pharma Inc aims to develop and commercialize pharmaceutical products that address unmet medical needs. By prioritizing patient well-being, the company strives to provide effective and safe treatments. Through their dedication to scientific advancements and ethical practices, Targeted Medical Pharma Inc sets a high standard in the medical industry.

Converted at the current exchange rate, the Targeted Medical Pharma share trades at 0.00 EUR (0.00 USD).

The company Targeted Medical Pharma Inc is a biopharmaceutical company that focuses on the development and marketing of innovative therapy products for various diseases. The business model of Targeted Medical Pharma is based on the production of pharmaceutical agents that are specifically tailored to the needs of patients. The company is divided into three business units: TmedPharma, TmedCRO, and TmedRx. TmedPharma specializes in the development of therapeutics for chronic metabolic disorders, as well as neurological and immunological diseases. TmedCRO offers clinical study services to other pharmaceutical companies, while TmedRx distributes dietary supplements and medical devices directly to consumers. Targeted Medical Pharma's products include therapeutics such as Theramine, a patented amino acid agent used to treat pain and inflammation. Avatrol is another product developed for the treatment of hemorrhoids. The company also offers NeuroReplete, a preparation for the treatment of metabolic disorders and neurological diseases. Another important aspect of Targeted Medical Pharma's business model is its partnership with leading medical institutions and organizations. The company collaborates with renowned universities and research institutions to test the effectiveness and safety of its products through clinical studies and research. These partnerships also serve as important marketing tools to increase awareness of the Targeted Medical Pharma brand among physicians and other healthcare professionals. Targeted Medical Pharma sells its products through a network of pharmacies, clinics, physicians, and online retailers. The company also holds several patents on its products and technologies, giving it a competitive advantage in the industry. In summary, Targeted Medical Pharma's business model is focused on developing and marketing innovative therapeutics for chronic metabolic disorders and neurological diseases. The company has three business units specializing in therapeutics development, clinical study services, and direct sales of dietary supplements and medical devices. Targeted Medical Pharma collaborates with leading institutions to test the effectiveness and safety of its products, and holds patents on its products and technologies, providing it with a competitive advantage in the industry.

The revenue cannot currently be calculated for Targeted Medical Pharma.

The profit cannot currently be calculated for Targeted Medical Pharma.

The P/E ratio cannot be calculated for Targeted Medical Pharma at the moment.

The P/S cannot be calculated for Targeted Medical Pharma currently.

The Eulerpool Quality Score for Targeted Medical Pharma is 1/10.

The ISIN of Targeted Medical Pharma is US8761401046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Targeted Medical Pharma is A1JFCJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Targeted Medical Pharma is TRGM. The ticker symbol is used to trade Targeted Medical Pharma shares on the stock exchange.

Targeted Medical Pharma paid dividends every year for the past 0 years.

Targeted Medical Pharma is assigned to the 'Health' sector.

The dividends of Targeted Medical Pharma are distributed in USD.

All fundamentals and in-depth analysis of Targeted Medical Pharma

Our stock analysis for Targeted Medical Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Targeted Medical Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Targeted Medical Pharma Stock
Targeted Medical Pharma Revenue→
Targeted Medical Pharma Stock
Targeted Medical Pharma Net Income→
Targeted Medical Pharma Stock
Targeted Medical Pharma P/E→
Targeted Medical Pharma Stock
Targeted Medical Pharma P/S→
Targeted Medical Pharma Stock
Targeted Medical Pharma EBIT→
Targeted Medical Pharma Stock
Targeted Medical Pharma Dividend→
Targeted Medical Pharma Stock
Targeted Medical Pharma Directors Dealings→
Targeted Medical Pharma Stock
Targeted Medical Pharma Stocks→
Targeted Medical Pharma Stock
Targeted Medical Pharma Market capitalization→
Targeted Medical Pharma Stock
Targeted Medical Pharma Debt→
Targeted Medical Pharma Stock
Targeted Medical Pharma Liabilities→
Targeted Medical Pharma Stock
Targeted Medical Pharma Equity→
Targeted Medical Pharma Stock
Targeted Medical Pharma AAQS→
Targeted Medical Pharma Stock
Targeted Medical Pharma Employees→
Targeted Medical Pharma Stock
Targeted Medical Pharma ROE→
Targeted Medical Pharma Stock
Targeted Medical Pharma ROA→
Targeted Medical Pharma Stock
Targeted Medical Pharma ROCE→
Targeted Medical Pharma Stock
Targeted Medical Pharma News→
Targeted Medical Pharma Stock
Targeted Medical Pharma Analyst Price Targets→

Health Stocks

Tarsons ProductsTarget GroupTarsus PharmaceuticalsTAO SynergiesTasly Pharmaceutical Group CoTanvex BioPharmaTaysha Gene TherapiesTango TherapeuticsTCI GeneTandem Diabetes CareTcm Biotech InternationalTalpheraAll Stocks A–Z →